What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Dette nettstedet er kun for helsepersonell som lege, offentlig godkjent sykepleier og farmasøyt

Lp(a) testing may improve CVC risk assessment in primary and secondary prevention settings

 

novartis_lp-a_illustration_digitala4_250605.png

Figure is adapted from Nurmohamed et al. Eur J Prev Cardiol. 2022;29(5):769-776

 

Following Lp(a) testing 
 

  • One in three patients with very elevated Lp(a) levels* were reclassified into a higher primary prevention risk category

  • 50% of all patients with very elevated Lp(a) levels* were reclassified into a higher seconday prevention risk category

 

 

SCORE: Conroy et al. Eur Heart J 2003;24:987–1003; https://www.heartscore.org/en_GB (Last accessed July 2024)

SMART: Dorresteijn et al. Heart 2013;99:866–872; https://u-prevent.com/calculators/smartScore (Last accessed July 2024);

*> 99th percentile, mean Lp(a) of 460 nmol/L. Back to the main page

 

Back to the main page